Linc

Linc Capital Intensity

The Capital Intensity Ratio of Linc (LINC.ST) as of Nov 20, 2026 is 45,781.45 %. In the previous year, Capital Intensity Ratio was 40.33 M % — a change of -99.89% (lower).

Capital Intensity

45,781.45 %

YoY

-99.89%

Last updated:

Capital Intensity Ratio of Linc is 2025 45,781.45 % . Capital Intensity Ratio of Linc was 2024 40.33 M % . It decreases by -99.89% lower compared to the previous year.

The Linc Capital Intensity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Capital Intensity
Date
Capital Intensity
Jan 1, 2018
18,607.50 SEK
Jan 1, 2019
35,962.34 SEK
Jan 1, 2020
201,250.27 SEK
Jan 1, 2021
90,947.58 SEK
Jan 1, 2022
122,836.06 SEK
Jan 1, 2023
96,766.33 SEK
Jan 1, 2024
40.33 M SEK
Jan 1, 2025
45,781.45 SEK
The Linc Capital Intensity history
YEARCapital IntensityYoY
45,781.45 %-99.89%
40.33 M %+41,576.13%
96,766.33 %-21.22%
122,836.06 %+35.06%
90,947.58 %-54.81%
201,250.27 %+459.61%
35,962.34 %+93.27%
18,607.50 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Linc Stock analysis

What does Linc do? Linc AB generates revenue through long-term share ownership in Nordic life science companies, focusing on pharmaceutical and medical technology sectors. The company invests in both private and public firms, including early-stage drug development and operational medical technology companies. Linc Invest actively supports portfolio companies by collaborating with management, founders, and boards to unlock growth potential and drive expansion. Its industrial network enables strategic participation in nomination committees and development planning. The firm targets Nordic life science product-oriented companies, prioritizing pharmaceuticals and medical technology. Investments span research and operational phases, with drug development typically occurring earlier than in medical technology. Linc AB maintains a hands-on approach as a long-term owner, leveraging its network to assist portfolio companies in achieving ambitious development goals. Linc AB's business model centers on active ownership and strategic partnerships within the Nordic life science ecosystem. It focuses on companies with strong product pipelines, particularly in pharmaceuticals, where investments often occur during initial development stages. The company's role as a supportive shareholder drives value creation through collaborative governance and targeted expansion strategies. Linc is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Linc stock

Capital Intensity Ratio of Linc is 45,781.45 % in 2025.

Capital Intensity Ratio of Linc changed from 40.33 M % to 45,781.45 %, representing a -99.89% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Capital Intensity Ratio Linc since 2006 – with annual values, charts, and detailed analysis.

Capital intensity measures the amount of assets needed to generate each unit of revenue. Lower ratios indicate asset-light business models.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Capital Intensity Ratio's Linc with sector peers and the industry average to assess whether it is attractive.

To evaluate Capital Intensity Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Capital Intensity Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Linc

All Key Metrics — Linc